A bill to identify and take action against international trade practices of high income countries that unfairly exploit innovation by deviating from market-based policies and unfairly exploit United States innovation, and for other purposes.
About This Bill
Committee
Latest Action · August 5, 2026
Read twice and referred to the Committee on Finance.
The USTRx Act, introduced in August 2026, aims to combat what Congress views as unfair pharmaceutical pricing practices by wealthy foreign countries. The bill creates a new Chief Pharmaceutical Trade Negotiator position within the U.S. Trade Representative's office to specifically handle pharmaceutical trade disputes and enforce agreements related to drug markets. The legislation requires the Trade Representative to annually report on pricing practices in high-income countries, identifying those that use government price controls or other policies that Congress believes undervalue American pharmaceutical innovation and unfairly shift drug development costs to U.S. patients and taxpayers. When the Trade Representative determines that a country's drug pricing policies harm American interests, the bill mandates submission of a response plan to Congress within 30 days, which may include initiating formal trade investigations under existing trade enforcement law. The bill reflects congressional concern that foreign governments' drug price negotiations reduce incentives for pharmaceutical companies to develop new medicines, ultimately limiting treatment options available to Americans.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.